DelveInsight launched a new report on Waldenstrom Macroglobulinemia Epidemiology Forecast, 2030.
Waldenstrom’s macroglobulinemia (WM) as lymphoma or cancer of the lymphatic system. It occurs in white blood cells called a B-lymphocyte or B-cell, which normally matures into a plasma cell that manufactures immunoglobulin to help the body fight infection. WM cells have characteristics of both B-lymphocytes and plasma cells and are hence classified as a type of non-Hodgkin’s lymphoma called lymphoplasmacytic lymphoma (LPL).
DelveInsight’s ‘Waldenstrom Macroglobulinemia Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Waldenstrom Macroglobulinemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Waldenstrom Macroglobulinemia Epidemiology Report:
As per the DelveInsight analysis, the total prevalent cases of Waldenstrom’s Macroglobulinemia were 32,852 in the 7MM in 2017, which is expected to grow at a CAGR of 0.68% for the study period 2017–2030.
The 7MM incident population was estimated to be 3817 cases in 2017, which is expected to grow at a CAGR of 0.79% during the forecast period 2017–2030.
As per the DelveInsight analysis, 8247 males and 4123 females were suffering from Waldenstrom’s Macroglobulinemia in 2017 in the US. These cases are further expected to increase by 2030.
In EU5, the highest incident cases were reported to be in Germany followed by France and the United Kingdom whereas the lowest incident rates were reported in Spain during the period 2017–2030.
Visit for more @ Waldenstrom Macroglobulinemia Epidemiology Insights
Scope of the Waldenstrom Macroglobulinemia Epidemiology report:
The Waldenstrom Macroglobulinemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
The Waldenstrom Macroglobulinemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Waldenstrom Macroglobulinemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Waldenstrom Macroglobulinemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Waldenstrom Macroglobulinemia
The report provides the segmentation of the Waldenstrom Macroglobulinemia epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Waldenstrom Macroglobulinemia
3. Waldenstrom Macroglobulinemia Epidemiology Overview at a Glance
4. Waldenstrom Macroglobulinemia: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Waldenstrom Macroglobulinemia
9. DelveInsight Capabilities
11. About DelveInsight
DelveInsight’s ‘Waldenstrom Macroglobulinemia-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
“Waldenstrom Macroglobulinemia Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Waldenstrom Macroglobulinemia market. A detailed picture of the Waldenstrom Macroglobulinemia pipeline landscape is provided, which includes the disease overview and Waldenstrom Macroglobulinemia treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States